Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| Medexus Lists October 2018 Unsecured Convertible Debentures on the TSX Venture Exchange | ||
| By: Nasdaq / GlobeNewswire - 12 Feb 2019 | Back to overview list |
|
MONTREAL, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (formerly Pediapharm Inc.) (the “Company”) (TSXV: MDP, OTCQB: PDDPF) today announced that the 6.0% unsecured convertible debentures of the Company (the “Debentures”) will commence trading on the TSX Venture Exchange under the symbol “MDP.DB” at the market opening today, Tuesday, February 12, 2019. The Debentures were issued on October 16, 2018 upon the automatic conversion of subscription receipts of the Company which were issued pursuant to a private placement of the Company on October 11, 2018. About Medexus Pharmaceuticals Inc. Medexus Pharmaceuticals Inc. is a leading specialty pharmaceutical company with a strong North American commercial platform. The Company’s vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork. Medexus Pharmaceuticals is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo and Metoject, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action. For more information, please contact: Ken d’Entremont, Chief Executive Officer Roland Boivin, Chief Financial Officer Investor Relations: Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. |
||
|
||
 | Back to overview list | |